Rejoint TAB

Quick links to important sections

Rejoint TAB

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rejoint TAB

Quick Facts about Rejoint TAB

Property Description
Active ingredient Glucosamine sulfate, Chondroitin sulfate
Form Oral solid dosage form (Tablet)
Pharmacological class Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA)
Common use Joint health support; structural component supply
Origin Derived from natural sources (shellfish/cartilage)

What Type of Preparation is Rejoint TAB?

Rejoint TAB is a combination product delivered as an oral solid dosage form (a tablet), classified as a medicinal preparation for musculoskeletal and joint support. Its high-level classification places it within the family of Symptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA), serving as a specialized nutritional supplement or adjuvant therapy. This SYSADOA designation means its benefits are realized gradually, aiming to support the structural components of the joints over time. These agents function by modulating cartilage metabolism and supporting the body's natural processes. This medicine aids in supporting the integrity of joint structure by influencing the components of cartilage.


Composition and Origin: Glucosamine and Chondroitin

The preparation contains two principal active pharmaceutical ingredients: Glucosamine sulfate and Chondroitin sulfate. These are Glycosaminoglycan derivatives and are foundational structural elements naturally found in the cartilage matrix and connective tissues. Both are generally derived from natural sources—Glucosamine often from shellfish and Chondroitin from animal cartilage—and are processed into stable salt forms for reliable oral consumption (per os). These specific sulfate salts serve a structural role in the body's connective tissues. The combination is intended for patients seeking joint health support during periods of wear and tear, such as among the elderly population or individuals with musculoskeletal strain.


General Purpose: Joint Health Support

The general purpose of Rejoint TAB is to provide comprehensive joint health support. By supplying precursors for cartilage formation and structural maintenance, the combination product aims to maintain the resilience and flexibility of the joints. This supportive function helps mitigate stiffness and discomfort associated with the natural wear and tear of the musculoskeletal system, which often presents as joint pain or reduced mobility in the adult population. The preparation is specifically positioned to offer dual-action support to the joint structure, differentiating it from formulations that target only pain or inflammation.

Regulatory References

  1. NIH Fact Sheet on Glucosamine and Chondroitin

What side effects are possible with Rejoint TAB?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety characteristics for preparations containing Glucosamine sulfate and Chondroitin sulfate, as documented in government regulatory sources. These statements are not medical advice.

Documented Adverse Reactions

The most common adverse reactions are typically mild and transient, primarily affecting the gastrointestinal system. Regulatory documents classify side effects by frequency:

Classification Examples of Side Effects
Common (1/100 to < 1/10) Nausea, abdominal pain, indigestion, flatulence, constipation, diarrhea, headache, somnolence, dizziness.
Uncommon (1/1,000 to < 1/100) Rash, itching, flushing.
Not Known Allergic reaction, insomnia, vomiting, visual disturbances, fatigue.

Serious Safety Considerations

Official labeling documents severe reactions that may require immediate attention, including severe allergic reactions such as angioedema (swelling) and breathing difficulties, particularly in predisposed individuals. The worsening or exacerbation of asthma symptoms has also been described following treatment initiation.

Population-Specific Safety Statements

  • Contraindications: The product is strictly contraindicated in patients with known hypersensitivity to the active ingredients or who have an allergy to shellfish, as the ingredients are often derived from this source.
  • Anticoagulant Use (Warfarin): Patients taking oral vitamin K antagonists (e.g., warfarin) require close monitoring of their coagulation parameters (INR) when starting or stopping this product, due to reported fluctuations.
  • Diabetes Mellitus: Caution is advised; closer monitoring of blood glucose levels is recommended for diabetic patients.
  • Use in Specific Groups: The product is not recommended for use in children and adolescents under 18 years of age, or in women who are pregnant or breastfeeding, due to a lack of established safety and efficacy data.

Overdose and Emergency Response

Overdose and When to Seek Help

In the event of a suspected or accidental overdose of Rejoint TAB, regulatory guidance mandates that an individual must seek immediate medical attention or contact a health professional immediately.

Overdose may present with an exacerbation of common gastrointestinal disturbances, though toxic effects and symptoms are generally considered unlikely to occur even at high dose levels, based on available toxicological data. Documented clinical manifestations of excessive consumption include nausea, abdominal pain, and diarrhea.

The primary concern associated with excessive intake involves the hepatic system, as reports have documented the potential for severe outcomes such as severe hepatitis and hepatic failure. This risk highlights the need for immediate clinical assessment. Furthermore, regulatory documents advise caution regarding administration to patients with pre-existing severe hepatic insufficiency or severe renal insufficiency.

Management of an overdose involves the discontinuation of treatment and the administration of symptomatic and standard supportive measures, such as action to restore the hydro electrolyte balance if necessary. No specific antidote is known for this product. Monitoring of liver enzymes may be required due to the risk of hepatic involvement.

Therapeutic Uses of Rejoint TAB

Quick Facts

  • Primary Use: Management of the symptoms associated with osteoarthritis.
  • Key Benefits: May help alleviate joint discomfort, reduce stiffness, and support physical function.
  • Joint Support: Helps support the health and maintenance of cartilage.

Rejoint TAB is a medication used to help manage the symptoms associated with osteoarthritis and other related joint conditions. The primary therapeutic goal is to assist patients in achieving relief from joint discomfort and stiffness, which may contribute to improved mobility and overall function in the affected areas, such as the knees and hips.

This medication may help to reduce discomfort and swelling in the joints by addressing symptoms related to inflammation. It is also indicated for the maintenance of joint health, as it may support the structure of cartilage, the soft tissue that cushions the joints, and help enhance lubrication for smoother movement. The medication is an important part of a comprehensive management plan for those experiencing joint wear and tear.

The use of these components is intended for the management of moderate-to-severe joint pain, providing a basis for healthcare professionals in supporting patient care. Individual responses to this medication may vary.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Rejoint TAB?

The population eligibility for Rejoint TAB, a combination product of Glucosamine sulfate and Chondroitin sulfate, is strictly defined by regulatory authorities through specific contraindications and required cautions.

Absolute Contraindications (Must Not Use)

Population Group Restriction Reason
Hypersensitivity Known allergy to the active ingredients or any excipients.
Shellfish Allergy Contraindicated due to Glucosamine typically being derived from shellfish.
Children and Adolescents Contraindicated under 18 years; safety and efficacy are not established.

Populations Requiring Caution or Supervision

Population Group Official Caution
Diabetic Patients Use requires closer monitoring of blood glucose levels.
Asthmatic Patients Caution is advised due to potential exacerbation of asthma symptoms.
Severe Renal/Hepatic Insufficiency Administration should be under medical supervision.

Pregnancy and Lactation

Use is not recommended during pregnancy or breastfeeding due to insufficient available regulatory data regarding safety for the unborn child or infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Rejoint TAB’s interaction profile is defined by specific drug-drug effects documented by regulatory authorities, requiring attention to certain co-administered medicines.

Interactions with Coumarinic Anticoagulants

The most clinically significant interaction involves co-administration with coumarinic anticoagulants, such as Warfarin. Official reports indicate that combining Rejoint TAB with these medicines can result in an increased International Normalised Ratio (INR) parameter, which reflects an enhanced anticoagulant effect. Due to this pharmacodynamic interaction, regulatory documentation specifies that close monitoring of coagulation parameters is required when initiating or discontinuing Rejoint TAB therapy in patients taking anticoagulants.

Other Documented Interactions

A separate pharmacokinetic-type interaction is documented with Tetracyclines. Co-administration of Glucosamine sulfate can enhance the gastrointestinal absorption of tetracycline medicines, potentially leading to increased systemic exposure. The official labeling explicitly states that Rejoint TAB can be administered together with non-steroidal analgesic or anti-inflammatory agents (NSAIDs). Furthermore, formal testing has demonstrated that Glucosamine sulfate does not inhibit the activity of major Cytochrome P450 enzymes (e.g., CYP3A4, CYP2D6), classifying the potential for broad CYP-mediated drug metabolism interactions as low.

Mechanism of Action

The mechanism of Rejoint TAB (Glucosamine sulfate and Chondroitin sulfate) is classified by its structural and regulatory influence on joint tissue metabolism. It operates by modulating the anabolic-to-catabolic balance within the articular cartilage, characterized by a slow onset and persistent mechanistic effect.

Glucosamine sulfate functions as a direct precursor and stimulator for chondrocytes, influencing the biosynthesis of crucial Extracellular Matrix (ECM) components like Proteoglycans and Glycosaminoglycans (GAGs). This structural modulation affects the cartilage's capacity for water retention, influencing its intrinsic viscoelasticity and resilience.

Chondroitin sulfate provides the protective, anti-catabolic signal. It acts as a modulator and inhibitor by downregulating the activity of destructive enzymes, specifically Matrix Metalloproteinases (MMPs), which drive tissue breakdown. Simultaneously, it influences pro-inflammatory signaling pathways, such as NF-κB, thereby reducing the local concentration of inflammatory mediators within the joint. This complementary interaction establishes a more stable physiological state in the joint tissues.

Dosage and Administration Information

How to Use Rejoint TAB

The administration of Rejoint TAB, a combination product containing Glucosamine sulfate and Chondroitin sulfate, follows a standardized protocol. The medicine is intended for oral use, delivered as a solid dosage form. The standard adult regimen involves a daily amount of 1500 mg of Glucosamine sulfate and 1200 mg of Chondroitin sulfate, typically taken as a single once daily dose. To support optimal absorption and tolerability, it is recommended to administer the tablet with or preferably at meals.

The medicine is classified as a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA), meaning it is not indicated for immediate relief of acute pain. Its therapeutic use is structured around a long-term approach; symptomatic effects may not be observed until after two to three months of continuous administration. If no symptomatic change is noted after this initial period, the continuation of the treatment course should be medically re-evaluated.

In terms of specific patient populations, this medicine is not recommended for use in individuals under 18 years of age. While formal dose adjustments are not outlined for organ impairment, treatment for patients with severe hepatic or renal conditions requires medical supervision.

Administration Detail Requirement
Route Oral administration (per os)
Frequency Once daily (single dose)
Timing With or at mealtime
Duration Principle Must be continuous for 2-3 months before re-evaluation

Recent Clinical Evidence

Research evidence / Overview of studies for Rejoint TAB

Evidence for use in [Indication 1: Mild to Moderate Osteoarthritis of the Knee]

This section will summarize the research studies—including clinical trials—that have evaluated changes in symptoms and joint function in people with mild to moderate knee osteoarthritis.

Research has examined Rejoint TAB in individuals who have conditions characterized by fluctuating or episodic manifestations like mild to moderate knee osteoarthritis. Studies monitored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. These trials explored how patients reported their experience over defined time intervals, usually short-term (e.g., up to 12 weeks).

The findings describe patterns observed in the studies. Research has explored the patterns of change in outcomes related to physical discomfort compared with groups receiving an inactive substance. However, in this research, the reported findings were inconsistent, showing varying degrees of difference between the study groups.

Evidence for use in [Indication 2: Improving Joint Mobility in Healthy Adults]

This part will outline the studies and research findings focusing on the use of Rejoint TAB in generally healthy adults seeking to support overall joint flexibility, mobility, and comfort.

Research was conducted to evaluate joint movement and flexibility in healthy individuals without a diagnosed joint condition. These studies were conducted during periods of increased symptom activity or in observational settings evaluating daily-life functioning where outcomes reflecting daily functioning or activity level were the focus.

In some participants, the data show patterns related to how patient-reported outcomes for perceived discomfort and flexibility evolved after physical activity. Research explored the product's use in individuals looking to maintain physical resilience.

Long-term studies and follow-up

This section will summarize the available evidence regarding how long changes measured in the studies may last, including information on extended observation periods.

Follow-up durations were limited in most of the existing research, meaning there is insufficient information on long-term outcomes for subjects in the studies. The available evidence is limited on the long-term patterns of change in outcomes related to physical discomfort or outcomes reflecting daily functioning or activity level.

Evidence in special populations

This section will outline any research that has investigated the use of Rejoint TAB in specific patient groups, such as older adults, or individuals with certain other health conditions, highlighting areas where evidence may be limited or where specific studies have been conducted.

Research information for specific populations, such as those with certain comorbid conditions or distinct age groups, remains limited. The available research is predominantly based on a specific adult demographic, and therefore, subgroup findings are uncertain.

What is still uncertain about Rejoint TAB

This concluding section will synthesize and clearly state the main gaps in the current research evidence, highlighting any findings that are inconsistent across studies and specifying the areas where more scientific investigation is needed to fully understand the patterns related to Rejoint TAB use.

There are remaining areas that require further research. First, comparative evidence is lacking, and second, the evidence quality varies across studies, and findings were mixed or inconsistent. Third, long-term effects are not fully established, and research is ongoing to understand long-term outcomes.

Frequently Asked Questions (FAQ)

Common questions about Rejoint TAB (FAQ)


Q: Is Rejoint TAB the same kind of medicine as Advil or Tylenol?

No, official product information describes Rejoint TAB as a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA). This classification indicates its primary purpose is to support the structural components of joint cartilage over time.

Medicines like Advil (ibuprofen) or Tylenol (acetaminophen) are classified as fast-acting analgesics that primarily provide immediate relief from pain or fever.


Q: Why do people say Rejoint TAB is different from other joint supplements?

Rejoint TAB is distinguished by its regulatory status and its combination of Glucosamine sulfate and Chondroitin sulfate.

These specific ingredients and their formulation lead to its classification as a SYSADOA by regulatory bodies. This classification sets it apart from general, single-ingredient nutritional supplements.


Q: Does Rejoint TAB interact with common vitamins or supplements?

Official regulatory documentation focuses primarily on drug-drug interactions, specifically listing interactions with coumarinic anticoagulants (like Warfarin) and Tetracyclines.

Information on interactions with common over-the-counter vitamins or mineral supplements is generally not listed in the main product documents.


Q: Are there any foods or drinks I should avoid while using Rejoint TAB?

Official instructions advise taking Rejoint TAB with or preferably at meals to help with absorption and tolerability.

The most critical restriction is for individuals with a known shellfish allergy, for whom the product is formally contraindicated because its active ingredients are often derived from shellfish sources.


Q: Is Rejoint TAB ever used for conditions other than joint problems?

The regulatory-approved use of Rejoint TAB, according to official documents, is specifically limited to the treatment of mild to moderate osteoarthritis and general joint health support.

Its classification as a SYSADOA reflects this focus on modulating joint tissue metabolism.


Q: Is Rejoint TAB an addictive medicine?

No. Regulatory bodies do not classify Rejoint TAB as a controlled substance in any official drug schedules.

The product is not associated with dependency or addiction.


Q: Where can I find the official regulatory information about Rejoint TAB?

Official regulatory information can be found in documents like the Summary of Product Characteristics (SmPC), which is filed with agencies such as the European Medicines Agency (EMA).

Equivalent documents are available on the websites of national drug authorities, such as the FDA DailyMed or national drug registries.


Q: Is Rejoint TAB available without a prescription in some places?

Preparations containing Glucosamine and Chondroitin sulfate may be available either as a prescription medicine or as an over-the-counter (OTC) supplement.

The specific regulatory status of Rejoint TAB as a product depends on the country where it is marketed and its particular formulation.


Q: Can Rejoint TAB be crushed or split?

Rejoint TAB is provided as an oral solid dosage form (a tablet).

Official regulatory documentation does not contain instructions to crush or split the tablet, and it is generally described as being swallowed whole.


Q: What is the difference between Rejoint TAB and the injection version (if one exists)?

Official regulatory documents formally describe Rejoint TAB as an oral solid dosage form (tablet).

While other formulations, like injections containing Glucosamine or Chondroitin components, may exist, they are separate medicinal preparations with distinct regulatory profiles, uses, and administration routes.


Q: Can Rejoint TAB affect the results of any lab tests?

Yes, official documentation describes one specific interaction affecting lab tests.

If co-administered with coumarinic anticoagulants (such as Warfarin), there can be an increase in the International Normalised Ratio (INR) parameter, which is a common blood clotting test.


Q: Does Rejoint TAB have any warnings for people with heart conditions?

Official product information does not list general heart conditions as a formal contraindication for use.

However, patients using the blood thinner Warfarin have an official caution requiring close monitoring of their blood coagulation parameters, as documented in the Interactions section.


Q: What happens if I accidentally take more Rejoint TAB than prescribed?

Regulatory guidance on accidental high intake suggests that common symptoms of overdose may be limited to gastrointestinal issues, headache, and dizziness.

Official guidance specifies that a healthcare provider should be contacted immediately in the event of accidental high intake.


Q: Is Rejoint TAB available as a generic medicine?

Products containing Glucosamine and Chondroitin sulfate are marketed under various brand names and generic combinations globally.

The availability of Rejoint TAB specifically as a generic medicine depends on the patent status of its particular formulation and approval by local regulatory agencies.


Q: Why might Rejoint TAB be contraindicated for people with specific eye conditions?

Eye conditions are not listed as a formal contraindication in the official product information.

However, some studies have suggested a potential association between Glucosamine use and an increase in intraocular pressure (IOP), which may be of interest for individuals with glaucoma.


Q: Is Rejoint TAB known to cause weight gain or loss?

According to the official Summary of Product Characteristics, neither weight gain nor weight loss is explicitly listed among the documented common, uncommon, or rare adverse reactions.

Weight changes have been mentioned in some less formal safety reports, but are not formally classified as a standard side effect.


How should Rejoint TAB be stored and disposed of?

Storage Requirements

Rejoint TAB must be stored according to label instructions to maintain its stability. The required storage temperature is below 30 C or within the range of 15 C to 30 C. It is mandatory to store the medicine in a dry place, protected from light and moisture. To preserve the tablets' integrity, they must remain in the original container and the container must be kept tightly closed.

Child-Safety and Disposal

For safety, Rejoint TAB must be stored out of the sight and reach of children and pets, as required by pharmaceutical regulation. Unused or expired medicine must be disposed of properly according to local regulations. Official guidance recommends using a drug take-back program or following the household disposal procedure to avoid flushing the product into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Rejoint TAB found in:

A-Z Index: